BioArctic

BioArctic Forward P/E

The Forward P/E Ratio of BioArctic (BIOA B.ST) as of Oct 4, 2026 is 26.77. In the previous year, Forward P/E Ratio was -154.58 — a change of -117.32% (higher).

Forward P/E

26.77

YoY

-117.32%

Last updated:

Forward P/E Ratio of BioArctic is 2026 26.77 . Forward P/E Ratio of BioArctic was 2025 -154.58 . It decreases by -117.32% higher compared to the previous year.

The BioArctic Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
71.73 SEK
Jan 1, 2019
309.41 SEK
Jan 1, 2020
-399.50 SEK
Jan 1, 2021
-228.51 SEK
Jan 1, 2022
-2,448.78 SEK
Jan 1, 2023
119.40 SEK
Jan 1, 2024
-154.58 SEK
Jan 1, 2025
26.77 SEK
The BioArctic Forward P/E history
YEARForward P/EYoY
26.77-117.32%
-154.58-229.46%
119.40-104.88%
-2,448.78+971.65%
-228.51-42.80%
-399.50-229.12%
309.41+331.34%
71.73-96.03%
1,805.93+279.89%
475.38-93.56%
7,378.03—
Access this data via the Eulerpool API

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

Forward P/E Ratio of BioArctic is 26.77 in 2026.

Forward P/E Ratio of BioArctic changed from -154.58 to 26.77, representing a -117.32% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio BioArctic since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's BioArctic with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — BioArctic

All Key Metrics — BioArctic